MarketCap
Facebook
X
Telegram
Recro Pharma DSO Ratio | REPH
Annual DSO Ratio Recro Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.7 | 56.4 | 50.7 | 64.3 | 50.1 | 53.2 | 51.1 | 50 | 30.1 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.3 | 30.1 | 52.1 |
Quarterly DSO Ratio Recro Pharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.6 | 64.4 | 66.1 | - | 71.1 | 60.4 | 56 | - | 66.4 | 63.9 | 58.3 | - | 59.7 | 76.6 | 60.5 | - | 61.5 | 49.6 | 52.9 | - | 58.4 | 45.1 | 45.6 | - | 61.9 | 60.3 | 55.2 | - | 64.3 | 62.5 | 53.4 | - | 67.8 | 57.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.6 | 45.1 | 59.9 |
DSO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
55.1 | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
71.3 | - | 2.45 % | $ 38.1 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
86.6 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
61.7 | $ 3.26 | 0.62 % | $ 1.25 B | Canada |
 |
China Pharma Holdings
CPHI
|
20.9 | $ 0.82 | 0.1 % | $ 3.52 M |  China |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
71.7 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
117 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
63.1 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
122 | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
49.9 | - | - | $ 2.06 B |  France |
 |
Athenex
ATNX
|
89.9 | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
382 | $ 6.79 | 0.59 % | $ 101 M | USA |
 |
Catalent
CTLT
|
80.1 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
96.2 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
65.5 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
79.9 | - | - | $ 28.9 M |  Irlanda |
 |
Jupiter Wellness
JUPW
|
51.9 | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
62.9 | $ 9.3 | 2.76 % | $ 600 M | USA |
 |
Lannett Company
LCI
|
83.1 | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.46 | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
268 | - | - | $ 150 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |
 |
Radius Health
RDUS
|
34.7 | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
43.1 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
14.1 | - | -27.8 % | $ 2.56 M | USA |
 |
OrganiGram Holdings
OGI
|
93 | $ 1.16 | 0.42 % | $ 111 M | Canada |
 |
Harrow Health
HROW
|
87.8 | $ 38.54 | 0.73 % | $ 1.42 B | USA |
 |
Zomedica Corp.
ZOM
|
31 | - | -0.21 % | $ 98 M | USA |
 |
Bausch Health Companies
BHC
|
79.8 | $ 6.56 | 5.56 % | $ 2.43 B | Canada |
 |
Emergent BioSolutions
EBS
|
58.6 | $ 6.21 | 0.08 % | $ 332 M | USA |
 |
Rockwell Medical
RMTI
|
43.3 | $ 7.99 | 1.31 % | $ 287 M | USA |
 |
Organogenesis Holdings
ORGO
|
106 | $ 1.71 | 4.27 % | $ 217 M | USA |
 |
Perrigo Company plc
PRGO
|
53.9 | $ 14.92 | 4.56 % | $ 2.07 B | USA |
 |
Tilray
TLRY
|
49.6 | $ 4.5 | 0.22 % | $ 4.01 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
44.5 | $ 1.33 | 0.38 % | $ 2.24 M | USA |
 |
SCYNEXIS
SCYX
|
2.74 | $ 5.3 | 0.47 % | $ 265 M | USA |
 |
Veru
VERU
|
91.5 | $ 2.64 | 0.94 % | $ 38.7 M | USA |
 |
Viatris
VTRS
|
67 | $ 16.88 | 0.03 % | $ 19.4 B | USA |
 |
TherapeuticsMD
TXMD
|
2.3 K | $ 2.21 | 0.22 % | $ 25.6 M | USA |
 |
cbdMD
YCBD
|
13.4 | $ 0.5 | 4.68 % | $ 2.01 M | USA |
 |
Canopy Growth Corporation
CGC
|
50.5 | $ 0.97 | 0.17 % | $ 289 M | Canada |
 |
ProPhase Labs
PRPH
|
907 | - | - | $ 5.07 M | USA |
 |
Aurora Cannabis
ACB
|
99.8 | $ 3.95 | 1.54 % | $ 217 M | Canada |